Sana Biotechnology (SANA) EBT (2020 - 2026)

Sana Biotechnology (SANA) has 7 years of EBT data on file, last reported at -$162.4 million in Q1 2026.

• For the quarter ending Q1 2026, EBT rose 25.17% year-over-year to -$162.4 million; the trailing twelve-month figure through Mar 2026 stood at -$534.9 million (up 16.4% YoY), and the FY2025 full-year result was -$369.6 million, down 5.54% from the prior year.
• EBT retreated to -$162.4 million in Q1 2026, from -$61.2 million in the prior quarter.
• In the past five years, EBT ranged from a high of -$52.4 million in Q4 2024 to a low of -$493.1 million in Q4 2023.
• A 5-year average of -$193.9 million and a median of -$196.7 million in 2024 frame the typical range for EBT.
• Across the five-year window, EBT tumbled 773.18% in 2022 and surged 89.38% in 2024, its largest moves.
• Tracing SANA's EBT over 5 years: stood at -$83.4 million in 2022, then sank by 491.21% to -$493.1 million in 2023, then surged by 89.38% to -$52.4 million in 2024, then fell by 16.82% to -$61.2 million in 2025, then slumped by 165.42% to -$162.4 million in 2026.
• Business Quant data shows SANA's EBT at -$162.4 million in Q1 2026, -$61.2 million in Q4 2025, and -$86.1 million in Q3 2025.